NCT05963048

Rituxmab Versus IL-6 in Treating ILD

Comparative Study About Effect of Rituximab Versus IL-6 Inhibitor in Induction of Remission in Active ILD in Scleroderma Patients

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

All SSc patients should know if they have been diagnosed with interstitial lung disease, or pulmonary hypertension and keep results from his/her last pulmonary function test, chest imaging, echocardiogram and stress test

Detailed description

All SSc patients should know if they have been diagnosed with interstitial lung disease, or pulmonary hypertension and keep results from his/her last pulmonary function test, chest imaging, echocardiogram and stress test Diffuse infiltrative lung disease (ILD): progressive shortness of breath is the most frequently presentation going to ER pulmonary unit first. It should be considered in case of persistent dry cough or dyspnea, which should be looked for in any patient with SSc. an etiological assessment must be conducted in order not to mistakenly attribute ILD to the SSc.

Conditions

• Interstitial Lung Disease
• Scleroderma

Interventions

Type	Name	Description
DRUG	Rituximab	IV infusion 1000 mg
DRUG	IL6 inhibitor	6 mg/kg I V infusion monthly

Timeline

• Start date: 2021-12-01
• Primary completion: 2022-12-30
• Completion: 2023-06-01
• First posted: 2023-07-27
• Last updated: 2023-11-15

Locations

1 site across 1 country: Egypt